Country: Կանադա
language: անգլերեն
source: Health Canada
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE)
FRESENIUS KABI CANADA LTD
J01FF01
CLINDAMYCIN
150MG
SOLUTION
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 150MG
INTRAMUSCULAR
2/6/60ML
Prescription
LINCOMYCINS
Active ingredient group (AIG) number: 0105830002; AHFS:
APPROVED
2006-10-05
_CLINDAMYCIN INJECTION, USP (Clindamycin Injection) _ _Page 1 of 37_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CLINDAMYCIN INJECTION, USP Clindamycin Injection Sterile Solution, 150 mg / mL clindamycin (as clindamycin phosphate), Intramuscular, Intravenous Antibiotic Fresenius Kabi Canada Ltd. 165 Galaxy Blvd, Suite 100 Toronto, ON M9W 0C8 Date of Initial Authorization: DEC 31, 1995 Date of Revision: MAY 24, 2022 Submission Control Number: 262504 _CLINDAMYCIN INJECTION, USP (Clindamycin Injection) _ _Page 2 of 37_ RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 05/2022 7 WARNINGS AND PRECAUTIONS, Renal 05/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ..................................................................................................2 TABLE OF CONTENTS ..................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .............................................................................4 1 INDICATIONS ..................................................................................................................4 1.1 Pediatrics..............................................................................................................5 1.2 Geriatrics ..............................................................................................................5 2 CONTRAINDICATIONS......................................................................................................5 4 DOSAGE AND ADMINISTRATION .......................................................................................5 4.1 Dosing Considerations ............................................................................................5 4.2 Recommended Dose and Dosage Adjustment ............................................................6 4.3 Reconstitution . read_full_document